Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.53 |
| ▸ | ELOVL1 | Q9BW60 | 10/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861545 | 0.84 | HTT (0.57) | HDAC4ALDH1A1SMN1; SMN2NPSR1HTT | |
| SCHEMBL2858307 | 0.82 | P2RX7 (0.57) | P2RX7HDAC4ELOVL1ALDH1A1NPSR1 | |
| SCHEMBL2857749 | 0.78 | ALDH1A1 (0.51) | HDAC4ELOVL1ALDH1A1NPSR1HTT | |
| SCHEMBL2867553 | 0.75 | SLC6A3 (0.48) | P2RX7HDAC4 | |
| SCHEMBL13593943 | 0.73 | HDAC1 (0.50) | HDAC4ELOVL1ALDH1A1NPSR1HTT | |
| SCHEMBL5366031 | 0.71 | HTT (0.60) | HDAC4ALDH1A1SMN1; SMN2NPSR1HTT | |
| SCHEMBL5923600 | 0.71 | P2RX7 (1.00) | P2RX7HDAC4SMN1; SMN2 | |
| SCHEMBL16132889 | 0.71 | HDAC4 (1.00) | HDAC4 | |
| SCHEMBL29825764 | 0.69 | FDPS (0.54) | ALDH1A1CNR2 | |
| SCHEMBL7599559 | 0.69 | FDPS (0.54) | ALDH1A1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050234106-A1 | Cycloalkyl inhibitors of potassium channel function | LLOYD JOHN | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234106-A1 | Cycloalkyl inhibitors of potassium channel function | KCNJ2, KCNN3, KCNQ5 | P2RX7 930/4885HDAC4 1442/4885ELOVL1 1086/4885 |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | P2RX7 930/4885HDAC4 1442/4885ELOVL1 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.